Literature DB >> 16403530

Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment.

Si-hai Ling1, Yi-lang Tang, Feng Jiang, Anna Wiste, Shi-shi Guo, Yong-zhen Weng, Tie-Sheng Yang.   

Abstract

PURPOSE: To examine the possibility that structural damage to the brain may play a role in the pathogenesis of schizophrenia by measuring the level of plasma S-100B, a calcium-binding protein found predominantly in the cytosol of glial cells.
METHOD: Fifty-seven Chinese psychiatric inpatients who met DSM-IV diagnosis of schizophrenia and 60 healthy controls were enrolled in the study. Patients were assessed with the Positive and Negative Symptoms Scale (PANSS) at admission and at 12 weeks after treatment. Plasma samples were collected from patients and controls and S-100B protein was assayed using ELISA.
RESULTS: (1) 29 of 57 patients (50.9%) showed increased S-100B level compared to the mean level of 60 healthy controls (p<0.005) vs. only 1 of 60 (1.67%) controls. The S-100B levels of unmedicated (0.119+/-0.059microg/L) and medicated patients (0.117+/-.0.057microg/L) were significantly higher than controls (0.067+/-0.022microg/L, both p<0.001), and S-100B levels of unmedicated patients were higher than those of medicated patients (p=0.024); (2) at admission, S-100B level was positively correlated with total score of PANSS (r=0.269, p=0.043), especially with negative subscore of PANSS (r=0.306, p=0.021), but the correlation was no longer present after patients were treated by anti-psychotic agents.
CONCLUSION: The S-100B levels of patients with schizophrenia are significantly higher than that of healthy controls, and the S-100B level is associated with severity of psychopathology, particularly negative symptoms, indicating that patients with schizophrenia may suffer structural damage to central nervous system. The concentration of S-100B may also be associated with treatment progress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16403530     DOI: 10.1016/j.jpsychires.2005.11.006

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  11 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia.

Authors:  Huiqiong Deng; Ramandeep S Kahlon; Satyajit Mohite; Pooja A Amin; Giovana Zunta-Soares; Gabriela D Colpo; Laura Stertz; Gabriel R Fries; Consuelo Walss-Bass; Jair C Soares; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2018-03

Review 3.  Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications.

Authors:  Trehani M Fonseka; Daniel J Müller; Sidney H Kennedy
Journal:  Mol Neuropsychiatry       Date:  2016-01-08

4.  S100B and homocysteine in the acute alcohol withdrawal syndrome.

Authors:  Dirk Wedekind; Karolin Neumann; Peter Falkai; Berend Malchow; Kirsten Rita Engel; Katja Jamrozinski; Ursula Havemann-Reinecke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-01       Impact factor: 5.270

5.  Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.

Authors:  Cristina S Benton; Brooke H Miller; Sean Skwerer; Oscar Suzuki; Laura E Schultz; Michael D Cameron; J S Marron; Mathew T Pletcher; Tim Wiltshire
Journal:  Psychopharmacology (Berl)       Date:  2011-11-24       Impact factor: 4.530

6.  Replicated evidence of absence of association between serum S100B and (risk of) psychotic disorder.

Authors:  Christine van der Leeuw; Machteld Marcelis; Sanne C T Peeters; Marcel M Verbeek; Paul P C A Menheere; Lieuwe de Haan; Jim van Os; Nico J M van Beveren
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

7.  Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.

Authors:  Wu Hong; Min Zhao; Haozhe Li; Fanglan Peng; Fan Wang; Ningning Li; Hui Xiang; Yousong Su; Yueqi Huang; Shengyu Zhang; Guoqin Zhao; Rubai Zhou; Ling Mao; Zhiguang Lin; Yiru Fang; Qinting Zhang; Bin Xie
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

8.  Bringing basic and clinical research together to an integrated understanding of psychiatric disorders.

Authors:  Marcus Ising
Journal:  J Psychiatr Res       Date:  2007 Jan-Feb       Impact factor: 4.791

Review 9.  Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.

Authors:  Katina Aleksovska; Emanuele Leoncini; Stefano Bonassi; Alfredo Cesario; Stefania Boccia; Alessandra Frustaci
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

10.  Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia-A Meta-Regression Analysis.

Authors:  Katharina Schümberg; Maryna Polyakova; Johann Steiner; Matthias L Schroeter
Journal:  Front Cell Neurosci       Date:  2016-02-25       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.